Sorafinib在HepG2人源肝癌BALB/C裸小鼠模型中的药效评价文献综述

 2023-02-26 11:02

附件：文献综述索拉菲尼在HepG2人源肝癌BALB/C裸小鼠模型中的药效评价摘 要：索拉菲尼（Sorafinib）是靶向血管内皮生长因子受体(vascular endothelial growth factor receptor, VEGFR)、B-Raf原癌基因(B-Raf proto-oncogene)等多种酪氨酸激酶的抑制剂, 具有同时抑制肿瘤细胞增殖和血管生成的双重作用。

临床研究揭示, 索拉菲尼能够显著延长晚期肝癌患者的存活时间。

目前肝癌的动物模型及药效评价的基础研究相对较少, 临床可用的肝癌靶向药物亦非常有限。

期望利用HepG2细胞作为造模细胞, 构建可用于临床肝癌治疗新药筛选的动物模型, 优化给药方式及药效评估方法, 为肝癌的新药筛选提供良好的动物实验体系的参考。

本文对索拉菲尼在HepG2人源肝癌BALB/C裸小鼠模型中的药效评价研究作一综述。

关键词：索拉菲尼；HepG2;肝癌；BALB/C裸小鼠；药效评价Efficacy Evaluation of Sorafenib in BALB/C Nude Mice Model of HepG2 Human Liver CancerAbstract：Sorafinib is targeting vascular endothelial growth factor receptor and B - Raf proto-oncogene and so on the many kinds of tyrosine kinase inhibitors, at the same time dual function of inhibiting tumor cell proliferation and angiogenesis. Clinical studies have revealed that sorafenib can significantly prolong the survival time of patients with advanced liver cancer. Currently, there are relatively few basic studies on animal models and pharmacodynamic evaluation of hepatocellular carcinoma, and the available targeted drugs for hepatocellular carcinoma are very limited. It is expected to use HepG2 cells as model cells to construct an animal model that can be used for the screening of new drugs for clinical liver cancer, optimize drug delivery methods and efficacy evaluation methods, and provide a good reference for the screening of new drugs for liver cancer in animal experiments. In this paper, the efficacy evaluation of sorafenib in BALB/C nude mouse model of HepG2 human liver cancer was reviewed.Key words：Sorafenib；HepG2；Liver Cancer；BALB/C Nude Mice；Efficacy evaluation肝细胞肝癌(hepatocellular carcinoma, HCC)(简称肝癌)是威胁人类健康的常见肿瘤之一, 并且在肿瘤相关性死亡中排第3位[1]。

肝癌是我国常见的恶性肿瘤，发病机制十分复杂。

且肝脏因其丰富的血供及淋巴管道循环，癌细胞极易发生扩散和转移，故晚期肝癌的死亡率极高。

1.研究背景目前, 人们对肝癌的研究多集中于细胞模型和临床患者, 对动物模型的研究较少[1]。

剩余内容已隐藏，您需要先支付 10元 才能查看该篇文章全部内容！立即支付

以上是毕业论文文献综述，课题毕业论文、任务书、外文翻译、程序设计、图纸设计等资料可联系客服协助查找。

您可能感兴趣的文章